ViiV Healthcare press release
ViiV Healthcare announced evidence from the OPERA observational cohort spanning five years of real-world use of Cabenuva (long-acting cabotegravir and rilpivirine [CAB+RPV LA]) for HIV treatment in the US and offering important insights into long-term clinical outcomes for adults living with HIV-1.
The study evaluated treatment durability – defined as maintaining viral suppression over time – and persistence, defined as remaining on therapy in routine care. In HIV care, durability and persistence are important clinical measures to help protect long-term health and prevent drug resistance. Among virologically suppressed adults in the United States who switched from oral antiretroviral therapy to CAB+RPV LA, after a median treatment duration of 18 months, the data highlight the sustained effectiveness of the long-acting injectable regimen for HIV treatment.
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.